Details

Autor(en) / Beteiligte

• Moyer, Tyson J
• Kato, Yu
• Abraham, Wuhbet
• Chang, Jason Y H
• Kulp, Daniel W
• Watson, Nicki
• Turner, Hannah L
• Menis, Sergey
• Abbott, Robert K
• Bhiman, Jinal N
• Melo, Mariane B
• Simon, Hayley A
• Herrera-De la Mata, Sara
• Liang, Shu
• Seumois, Gregory
• Agarwal, Yash
• Li, Na
• Burton, Dennis R
• Ward, Andrew B
• Schief, William R
• Crotty, Shane
• Irvine, Darrell J

Titel

Engineered immunogen binding to alum adjuvant enhances humoral immunity

Ist Teil von

• Nature medicine, 2020-03, Vol.26 (3), p.430-440

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Adjuvants are central to the efficacy of subunit vaccines. Aluminum hydroxide (alum) is the most commonly used vaccine adjuvant, yet its adjuvanticity is often weak and mechanisms of triggering antibody responses remain poorly understood. We demonstrate that site-specific modification of immunogens with short peptides composed of repeating phosphoserine (pSer) residues enhances binding to alum and prolongs immunogen bioavailability. The pSer-modified immunogens formulated in alum elicited greatly increased germinal center, antibody, neutralizing antibody, memory and long-lived plasma cell responses compared to conventional alum-adsorbed immunogens. Mechanistically, pSer-immunogen:alum complexes form nanoparticles that traffic to lymph nodes and trigger B cell activation through multivalent and oriented antigen display. Direct uptake of antigen-decorated alum particles by B cells upregulated antigen processing and presentation pathways, further enhancing B cell activation. These data provide insights into mechanisms of action of alum and introduce a readily translatable approach to significantly improve humoral immunity to subunit vaccines using a clinical adjuvant.